Article in Antimicrobial agents and chemotherapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Arne EchterhofDivision of Infectious Diseases and Geographic Medicine, Department of Medicine, Stanford University School of Medicine, Stanford, California, USA.ORCID 0009-0001-6963-9780
Tejas DharmarajDivision of Infectious Diseases and Geographic Medicine, Department of Medicine, Stanford University School of Medicine, Stanford, California, USA.ORCID 0000-0002-5305-9968
Patrick BlankenbergDivision of Infectious Diseases and Geographic Medicine, Department of Medicine, Stanford University School of Medicine, Stanford, California, USA.ORCID 0009-0009-1785-9392
Bobby TargDivision of Infectious Diseases and Geographic Medicine, Department of Medicine, Stanford University School of Medicine, Stanford, California, USA.
Thomas D NguyenDivision of Clinical and Translational Therapeutics, School of Pharmacy & Pharmaceutical Sciences, University at Buffalo, Buffalo, New York, USA.ORCID 0009-0000-1069-1720
Paul L BollykyDivision of Infectious Diseases and Geographic Medicine, Department of Medicine, Stanford University School of Medicine, Stanford, California, USA.ORCID 0000-0003-2499-9448
Nicholas M SmithDivision of Clinical and Translational Therapeutics, School of Pharmacy & Pharmaceutical Sciences, University at Buffalo, Buffalo, New York, USA.ORCID 0000-0002-0212-2787
Francis G BlankenbergDivision of Pediatric Radiology and Nuclear Medicine, Department of Radiology, Lucile Packard Children's Hospital, Stanford, California, USA.ORCID 0000-0002-6511-8849
Funding
Novel Strategies for Antibiotic Combinations to Combat Gram-negative SuperbugsR01AI148560 · NIAID · STATE UNIVERSITY OF NEW YORK AT BUFFALO · PI BULITTA, JURGEN BERND, TSUJI, BRIAN · 2020 to 2024
$3.9M
Novel Combination Therapies to Combat Hypermutable Carbapenem-Resistant P. aeruginosaR01AI165997 · NIAID · UNIVERSITY OF COLORADO DENVER · PI MARK D. SUTTON, Brian Tsuji · 2022 to 2026
$3.9M
Age and Race Influences on Immunosuppression after Renal TransplantR01AG056392 · NIA · STATE UNIVERSITY OF NEW YORK AT BUFFALO · PI TORNATORE, KATHLEEN M · 2018 to 2022
$3.5M
Pharmacokinetics and Pharmacodynamics of Mechanistically Aware Phage CocktailsR01AI177997 · NIAID · STATE UNIVERSITY OF NEW YORK AT BUFFALO · PI Nicholas Michael Smith · 2024 to 2026
$2.2M
Non-invasive Monitoring for Infections and Rejection after Lung TransplantationR01AI182349 · NIAID · STANFORD UNIVERSITY · PI Paul L Bollyky · 2024 to 2026
$1.8M
Pathogenesis of Pf Bacteriophages in Pseudomonas Cystic Fibrosis lung InfectionsR01HL148184 · NHLBI · STANFORD UNIVERSITY · PI MILLA, CARLOS · 2019 to 2022
$1.7M
Hydrogel Delivery of Bacteriophage to Treat Wound InfectionsR01EB038154 · NIBIB · STANFORD UNIVERSITY · PI Paul L Bollyky, Ovijit Chaudhuri · 2025 to 2026
$1.2M
Studies on bacteriophages in respiratory diseasesK24AI166718 · NIAID · STANFORD UNIVERSITY · PI Paul L Bollyky · 2022 to 2026
$815k
Antimicrobial peptides and antibiotic diffusion in sputumR21AI194044 · NIAID · STANFORD UNIVERSITY · PI BOLLYKY, PAUL L · 2025 to 2025
$424k
National Institute of Allergy and Infectious Diseases K24AI166718National Institute of Allergy and Infectious Diseases R01AI12492093National Institute of Allergy and Infectious Diseases R01AI148560National Institute of Allergy and Infectious Diseases R01AI165997National Institute of Allergy and Infectious Diseases R01AI177997National Institute of Allergy and Infectious Diseases R01AI182349NHLBI NIH HHS R01 HL148184NHLBI NIH HHS R01HL148184NIAID NIH HHS K24 AI166718NIAID NIH HHS R01 AI148560NIAID NIH HHS R01 AI165997NIAID NIH HHS R01 AI177997NIAID NIH HHS R01 AI182349NIAID NIH HHS R21 AI194044NIA NIH HHS R01 AG056392NIA NIH HHS R01AG056392NIBIB NIH HHS R01 EB038154Stanford Bio-XStanford Woods Institute for the Environment
6 · The paper itself
Abstract
Bacteriophage (phage) therapy holds great promise for treating antimicrobial-resistant infections. However, the pharmacokinetics (PK) of phage have been difficult to characterize due to a lack of standardized protocols for phage purification, labeling, and
Indexed as
Pseudomonas aeruginosaPseudomonas PhagesAnimalsFemaleMicePhage TherapyPseudomonas InfectionsTissue Distributionbacteriophagepharmacokineticsphysiologically based pharmacokineticPseudomonastranslational
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Whole-body distribution of three · full record | OpenQuestion